MATters of Excellence

Monthly updates from the New Jersey Medications for Addiction

Treatment Centers of Excellence

From Leaf to Lab: Kratom, 7-OH, and the Evolving Opioid Market

As the legal landscape surrounding kratom and 7-OH continues to evolve, individuals who have developed dependence on these widely available substances may face new challenges, including unexpected withdrawal.


On October 23, the Southern New Jersey Medications for Addiction Treatment Center of Excellence will host an online training exploring the changing regulatory environment, the risks associated with kratom and 7-OH dependence, and what clinicians need to know about recognizing and managing withdrawal symptoms.


Attendees will be eligible for up to two hours of AMA PRA Category 1 continuing medical education credits.


When: October 23, from 11 a.m.–1 p.m.

Presented by: William LaPlant, MD, and Shruti Gujaran, MD

Where: Virtual


Click to register

Nitazenes and Orphines: the Next Generation of Synthetic Opioids

In Jersey Drug Watch, Joseph D'Orazio, MD, an addiction medicine physician and expert toxicologist, breaks down current trends in the drug landscape for health care providers in the Garden State.


Illicitly manufactured fentanyl remains the dominant opioid in the U.S. drug supply and the primary driver of fatal opioid overdoses. However, an evolving group of highly potent, non-fentanyl synthetic opioids—including nitazenes and, more recently, orphines—is increasingly being detected, adding new complexity to an already unpredictable illicit drug supply.


Nitazenes are a family of non-fentanyl benzimidazole opioids first identified in the U.S. illicit drug supply in 2019. Detections expanded substantially through 2024, with newer analogues such as metonitazene and protonitazene replacing earlier compounds such as isotonitazene. Nitazenes are frequently found alongside fentanyl and other drugs rather than as standalone products, emphasizing that they currently represent an infiltration of a fentanyl-dominant supply rather than a replacement for fentanyl.


More recently, another class of highly potent synthetic opioids known as orphines has emerged. These include brorphine, chlorphine, spirochlorphine, and N-propionitrile chlorphine (cychlorphine). Following regulatory control of nitazenes in China in July 2025, CFSRE surveillance has shown declining nitazene positivity alongside increasing orphine detections, suggesting another potential shift in the illicit opioid supply.


Cychlorphine is of particular concern, with in vitro data suggesting potency approximately 10-fold greater than fentanyl and increasing detection in fatal overdoses since mid-2025. Confirmed cases have been identified across multiple U.S. states, including neighboring Pennsylvania. While these substances remain uncommon and their presence in the drug supply is unpredictable, their emergence demonstrates the continued evolution of the illicit opioid landscape.


For clinicians, the treatment of opioid overdose has not changed. Regardless of whether the opioid involved is fentanyl, carfentanil, a nitazene, an orphine, or another synthetic opioid, naloxone remains highly effective at reversing opioid-induced respiratory depression.

Leveling the Playing Field: Equipping Interdisciplinary Substance Use Teams with Skills for Whole-Person Care

As substance use disorder treatment becomes increasingly integrated into outpatient care, interdisciplinary teams play a growing role in supporting patients. Yet many team members have limited access to formal training in addiction medicine, harm reduction and patient-centered care.


To address this gap, the Camden Coalition developed a free, virtual Office-Based Addiction Treatment (OBAT) Care Team Training program for New Jersey's substance use disorder workforce. The five-course curriculum covers stigma, harm reduction, team collaboration and individualized care planning.


In a recent blog post, the Camden Coalition explores how the program equips professionals from diverse backgrounds with practical skills to deliver more coordinated, compassionate care and support patients in recovery.


Blog post

News: Dexmedetomidine Use and Intensive Care Unit Admissions for Patients With Medetomidine Withdrawal

As medetomidine becomes increasingly prevalent in the nation's illicit fentanyl supply, clinicians are encountering a severe withdrawal syndrome that may require intensive care.


A new research letter published in JAMA Internal Medicine examines the use of dexmedetomidine and ICU admissions among hospitalized patients with opioid use disorder, highlighting emerging challenges in managing withdrawal from this potent veterinary sedative.


JAMA Internal Medicine

News: How Should the Use of Opioids Be Regulated to Motivate Better Clinical Practice?

How have decades of opioid regulations shaped clinical practice, and are current policies doing more harm than good?


In this AMA Journal of Ethics article, researchers examine the history and consequences of U.S. opioid prescribing policies, including disparities in access to treatment for opioid use disorder.


AMA Journal of Ethics

The New Jersey Medications for Addiction Treatment Centers of Excellence were established in 2019 to serve as references for anyone interested in improving addiction care throughout the state. They meet this objective by offering educational lectures, shadowing opportunities, and otherwise general expertise to health care providers, schools, justice facilities, and more.


The Northern New Jersey Medications for Addiction Treatment Center of Excellence is administered by the Rutgers New Jersey Medical School Department of Psychiatry.


The Southern New Jersey Medications for Addiction Treatment Center of Excellence is administered by Cooper Norcross Health's Center for Healing, its addiction medicine program, and the Rowan-Virtua School of Osteopathic Medicine.


This newsletter is a collaboration between the two.